ClinicalTrials.gg
Not yet recruitingNCT07938255Updated Nov 16, 2026

Early- Warning and Precision-Intervention Technologies for Decline in Intrinsic Capacity

An interventional study of IC Management Platform with AI Health Coach and Multi-parameter Wearable Monitoring in Frailty at Older Adults, sponsored by The Fourth Affiliated Hospital of Zhejiang University School of Medicine. Not yet recruiting. Open to participants aged 18 Years to 100 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by The Fourth Affiliated Hospital of Zhejiang University School of Medicine · Not applicable, Interventional, and Prevention

Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
500
Allocation
Randomized
Ages
18 Years to 100 Years
Sex
All
01

Study summary

This clinical study aims to develop and apply early-warning and precision-intervention technologies for older adults with declining intrinsic capacity. It intends to identify key digital biomarkers, build dynamic prediction models, and verify the effectiveness of a human-computer interactive adaptive closed-loop intervention system, so as to shift geriatric health management from reactive medical care to proactive health management. The main questions it aims to answer are:

Can multi-modal digital data enable early warning of intrinsic capacity decline among community-dwelling older adults?

Does the AI-driven personalized stepped intervention reduce the incidence of intrinsic capacity decline and adverse health events in older adults?Researchers will compare an integrated whole-course intrinsic-capacity management platform intervention versus routine community-based geriatric health services through a cluster-randomized controlled trial.Participants will:

Complete baseline multi-modal assessments including standard scales and wearable-device-based physiological monitoring Receive follow-up assessments every 3-6 months for 12-24 months in the cohort phase Be assigned to either the intervention group or the control group for a 6-month intervention period Undergo multi-dimensional evaluations at baseline, month 3, month 6 and month 12 Comply with health-management requirements or routine community health services according to group assignment

02

Conditions studied

  • Frailty at Older Adults

Browse trials for

Keywords

  • ICOPE
  • older adults
  • community-dwelling
  • digital biomarker
  • artificial intelligence
  • intrinsic capacity
03

In context

Frailty

1,287 studies on the registry are indexed under Frailty; 454 are open to participants now.

This study's planned enrollment of 500 is above the median of 82 across 769 interventional studies indexed under Frailty.

Browse Frailty studies →

Lead sponsor

The Fourth Affiliated Hospital of Zhejiang University School of Medicine is the lead sponsor of 99 studies on the registry; 84 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 60 years or older
  • Residing stably in the affiliated community for at least 6 months
  • Conscious and able to cooperate with assessments and device operation (individuals at risk of mild cognitive impairment may participate with assistance)
  • Voluntary participation with written signed

Exclusion criteria

Exclusion Criteria:

  • Severe cognitive impairment or acute phase of psychiatric illness, unable to cooperate with assessment or intervention
  • Severe heart, lung, liver, or kidney failure, or terminal stage of malignant tumor
  • Skin damage, infection, or other conditions affecting wearing of wearable devices
  • Judged by the investigator to be unsuitable for participation in the study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
500 participants (estimated)

Study arms

  • Experimental
    Intervention

    Participants receive the Intrinsic Capacity (IC) whole-course management platform intervention for 6 months, with follow-up to 12 months. The intervention includes: (1) an LLM-driven multi-agent AI health coach (knowledge-delivery, empathetic communication, and quality supervision agents); (2) continuous wearable device monitoring (blood pressure, heart rate, activity pattern, sleep architecture, skin temperature, dual-task gait); and (3) risk-stratified, individualized stepped prescriptions covering five domains: nutrition, exercise, cognition, psychological health, and sensory function. The platform collects adherence data in real time and dynamically adjusts the intervention plan (Just-In-Time Adaptive Intervention, JITAI).

    Behavioral: IC Management Platform with AI Health Coach · Device: Multi-parameter Wearable Monitoring

  • No intervention
    Control

    Participants receive routine community health management services for older adults as usually provided by the community health service center, including regular physical examination and standard health education. Intervention duration is 6 months, with follow-up to 12 months.

Interventions

  • BehavioralIC Management Platform with AI Health Coach

    A multi-agent, LLM-driven AI health coach system (knowledge-delivery, empathetic communication, and quality supervision agents) combined with a Just-In-Time Adaptive Intervention (JITAI) decision engine, delivering risk-stratified, individualized stepped interventions across five domains: nutrition, exercise, cognition, psychological health, and sensory function. Delivered for 6 months via the IC whole-course management platform.

  • DeviceMulti-parameter Wearable Monitoring

    Wearable devices continuously monitor dynamic blood pressure, heart rate, activity patterns, sleep architecture, skin temperature, and dual-task gait. Device data are uploaded in real time to the platform and used to trigger adaptive, individualized intervention recommendations.

06

What researchers measure

Primary outcomes

  1. Incidence of Intrinsic Capacity Decline

    The proportion of participants who experience a clinically significant decline in at least one of the five WHO intrinsic capacity domains during follow-up. Each domain is assessed at baseline and at 3, 6, and 12 months using a single prespecified instrument: cognition (MoCA), locomotion (SPPB), psychological status (GDS-15), vitality (MNA-SF), and sensory function (vision and hearing tests). Each instrument is converted against a prespecified threshold into a binary decline judgement (yes/no). These five binary judgements are aggregated into one composite endpoint: a participant is counted as having an event if decline is present in any domain. Only one value is reported, the percentage of participants meeting this composite definition at 12 months, expressed as a percentage of participants.

    Time frame: From baseline to 12 months

  2. Incidence of Adverse Health Events

    The proportion of participants experiencing at least one event of a composite of adverse health events (falls, emergency department visits, hospitalizations, or death) during follow-up. Each event type is recorded as a binary occurrence and verified against medical records at the 3-, 6-, and 12-month assessments. The four event types are aggregated into a single composite binary endpoint: each participant is counted once if any component event occurs. Only one value is reported, the percentage of participants with at least one component event at 12 months, expressed as a percentage of participants.

    Time frame: From baseline to 12 months

Secondary outcomes

  1. Change in Cognitive Function (MoCA Score)

    Change from baseline in the Montreal Cognitive Assessment (MoCA) score at 3, 6, and 12 months. Reported as change in MoCA score points; only one value is reported.

    Time frame: Baseline to 12 months

  2. Change in Locomotion (SPPB Score)

    Change from baseline in the Short Physical Performance Battery (SPPB) score at 3, 6, and 12 months. Reported as change in SPPB score points; only one value is reported.

    Time frame: Baseline to 12 months

  3. Change in Psychological Status (GDS-15 Score)

    Change from baseline in the 15-item Geriatric Depression Scale (GDS-15) score at 3, 6, and 12 months. Reported as change in GDS-15 score points; only one value is reported.

    Time frame: Baseline to 12 months

  4. Change in Vitality / Nutritional Status (MNA-SF Score)

    Change from baseline in the Mini Nutritional Assessment Short-Form (MNA-SF) score at 3, 6, and 12 months. Reported as change in MNA-SF score points; only one value is reported.

    Time frame: Baseline to 12 months

  5. Change in Sensory Function Score

    Vision and hearing test results are converted according to a prespecified grading rule into a single sensory domain score ranging from 0 to 100. Change from baseline in this sensory domain score is assessed at 3, 6, and 12 months. Reported as change in score points; only one value is reported.

    Time frame: Baseline to 12 months

  6. Change in Intrinsic Capacity Digital Index

    Change from baseline in the composite Intrinsic Capacity Digital Index (0-10), derived by aggregating multimodal wearable and assessment data at 3, 6, and 12 months. Reported as change in index score points; only one value is reported.

    Time frame: Baseline to 12 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Aug 2028, 20 months later.

Of 514 non-industry interventional studies with no phase under Frailty, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 39. This study's planned 20 months is close to that.

Counting every sponsor, half of 518 studies reached it within 22 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 2, 2026
First posted
Nov 16, 2026
StartEst.
Dec 31, 2026
Primary completionEst.
Aug 31, 2028
CompletionEst.
Dec 31, 2028
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07938255
Lead sponsor
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Responsible party
Sponsor
First posted
Nov 16, 2026
Start date
Dec 31, 2026 (estimated)
Primary completion
Aug 31, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Nov 16, 2026

Study contacts

Huafang Zhang
Contact
wuyizhangyichi@zju.edu.cn
86-579-89935056

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion